[go: up one dir, main page]

AR114139A1 - Nano-partículas que contienen variantes sintéticas del gangliósido gm3 como adyuvantes en vacunas - Google Patents

Nano-partículas que contienen variantes sintéticas del gangliósido gm3 como adyuvantes en vacunas

Info

Publication number
AR114139A1
AR114139A1 ARP180103229A ARP180103229A AR114139A1 AR 114139 A1 AR114139 A1 AR 114139A1 AR P180103229 A ARP180103229 A AR P180103229A AR P180103229 A ARP180103229 A AR P180103229A AR 114139 A1 AR114139 A1 AR 114139A1
Authority
AR
Argentina
Prior art keywords
ganglioside
nano
adjuvant
synthetic variants
proteins
Prior art date
Application number
ARP180103229A
Other languages
English (en)
Inventor
Barranco Jess Arturo Lpez Lpez Miguel Antonio Junco
Murgua Blanca Idelmis Toln
Bencomo Vicente Guillermo Verez
Vargas Ngel Alexis Manso
Rodrguez Mabel Cruz
Fernndez Diana Rosa Hernndez
Martnez Dayana Prez
Surez Narjara Gonzlez
Garca Lisset Chao
Pardillo Circe Mesa
Bez Gretchen Bergado
Gmez Audry Fernndez
Ramrez Belinda Snchez
Molina Luis Enrique Fernndez
Original Assignee
Centro De Inmunología Molecular
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Centro De Inmunología Molecular filed Critical Centro De Inmunología Molecular
Publication of AR114139A1 publication Critical patent/AR114139A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001102—Receptors, cell surface antigens or cell surface determinants
    • A61K39/001103—Receptors for growth factors
    • A61K39/001106—Her-2/neu/ErbB2, Her-3/ErbB3 or Her 4/ErbB4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001144—Hormones, e.g. calcitonin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5161—Polysaccharides, e.g. alginate, chitosan, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5169—Proteins, e.g. albumin, gelatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55516—Proteins; Peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55588—Adjuvants of undefined constitution
    • A61K2039/55594—Adjuvants of undefined constitution from bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cell Biology (AREA)
  • Endocrinology (AREA)
  • Optics & Photonics (AREA)
  • Nanotechnology (AREA)
  • Biomedical Technology (AREA)
  • Physics & Mathematics (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)

Abstract

Se describe la forma de obtener adyuvantes nano-particulados basados en diferentes variantes sintéticas del gangliósido GM3. En dependencia de la estructura fina del ácido graso presente en el ceramido del GM3 sintético, se pueden obtener adyuvantes que sirven para estimular específica y especializadamente la respuesta inmune humoral o la celular contra antígenos acompañantes. Particularmente, Además provee composiciones vacunales inmunogénicas que comprenden péptidos, polipéptidos o proteínas y las antes mencionadas nano-partículas, que se forman mediante la dispersión de proteínas hidrofóbicas del complejo de membrana externa (CPME) de la bacteria Neisseria meningitidis con variantes totalmente sintéticas del gangliósido GM3. Reivindicación 1: Un adyuvante que comprende nano-partículas formadas mediante la asociación de variantes totalmente sintéticas del gangliósido GM3 a proteínas hidrofóbicas del complejo de membrana externa de la bacteria Neisseria meningitidis. Reivindicación 4: Una composición vacunal que comprende un adyuvante nano-particulado de cualquiera de las reivindicaciones 1 - 3 y como antígeno péptidos, polipéptidos o proteínas. Reivindicación 5: La composición vacunal de la reivindicación 4 que eventualmente comprende otro adyuvante seleccionado del grupo que comprende: alúmina y un adyuvante oleoso. Reivindicación 8: La composición vacunal de la reivindicación 4 - 6 donde el antígeno es el péptido PyrGnRHm1-TT.
ARP180103229A 2017-11-06 2018-11-06 Nano-partículas que contienen variantes sintéticas del gangliósido gm3 como adyuvantes en vacunas AR114139A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CU2017000137A CU24534B1 (es) 2017-11-06 2017-11-06 Adyuvantes nano-particulados que contienen variantes sintéticas del gangliósido gm3

Publications (1)

Publication Number Publication Date
AR114139A1 true AR114139A1 (es) 2020-07-29

Family

ID=64745822

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP180103229A AR114139A1 (es) 2017-11-06 2018-11-06 Nano-partículas que contienen variantes sintéticas del gangliósido gm3 como adyuvantes en vacunas

Country Status (18)

Country Link
US (2) US11806396B2 (es)
EP (1) EP3711775A1 (es)
JP (1) JP7332592B2 (es)
KR (1) KR102728174B1 (es)
CN (1) CN111295200B (es)
AR (1) AR114139A1 (es)
AU (1) AU2018359358B2 (es)
BR (1) BR112020008668A2 (es)
CA (1) CA3079105A1 (es)
CO (1) CO2020006548A2 (es)
CU (1) CU24534B1 (es)
EA (1) EA202091116A1 (es)
MX (1) MX2020004644A (es)
MY (1) MY204283A (es)
SG (1) SG11202004180SA (es)
TW (1) TWI719351B (es)
WO (1) WO2019086056A1 (es)
ZA (1) ZA202003218B (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CU24534B1 (es) 2017-11-06 2021-07-02 Ct Inmunologia Molecular Adyuvantes nano-particulados que contienen variantes sintéticas del gangliósido gm3
CU24637B1 (es) 2019-12-24 2022-12-12 Ct Ingenieria Genetica Biotecnologia Polipéptidos que comprenden mutantes del vegf-a humano con re-arreglos de puentes disulfuro y composiciones que los contienen
CU24705B1 (es) 2020-10-22 2024-06-11 Ct Ingenieria Genetica Biotecnologia Antígeno quimérico que comprende el dominio extracelular de pd-l1
CN121130071A (zh) * 2025-11-17 2025-12-16 重庆市畜牧科学院 一种含有免疫佐剂的多肽纳米颗粒疫苗及其制备方法和应用

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6149921A (en) * 1993-12-29 2000-11-21 Centro De Inmunologia Molecular Vaccine compositions for eliciting an immune response against N-acetylated gangliosides and their use for cancer treatment
IS4518A (is) * 1997-07-09 1999-01-10 Lyfjathroun Hf, The Icelandic Bio Pharmaceutical Group Nýtt lyfjaform fyrir bóluefni
PE20020572A1 (es) * 2000-12-06 2002-07-31 Centro Inmunologia Molecular Preparaciones para potenciar la inmunogenicidad de antigenos poco inmunogenicos
CU23257A1 (es) * 2003-02-27 2008-01-24 Centro Inmunologia Molecular COMPOSICIONES VACUNALES A BASE DE GANGLIOSIDOS PARA LA ADMINISTRACION SUBCUTáNEA
US7776346B2 (en) 2003-05-22 2010-08-17 Unilever Home & Personal Care Usa, Division Of Conopco, Inc. Personal product compositions comprising structured benefit agent premix or delivery vehicle
GB0323965D0 (en) * 2003-10-13 2003-11-19 Glaxosmithkline Biolog Sa Immunogenic compositions
CU23739A1 (es) * 2008-09-30 2011-12-28 Ct Ingenieria Genetica Biotech Composición farmacéutica utilizando combinaciones de variantes de la hormona liberadora de las gonadotropinas (gnrh) como inmunógeno
US8343498B2 (en) * 2008-10-12 2013-01-01 Massachusetts Institute Of Technology Adjuvant incorporation in immunonanotherapeutics
CU24299B1 (es) * 2013-08-02 2017-12-08 Centro De Inmunología Molecular Composiciones vacunales bivalentes basadas en los receptores de tipo 1 y 2 del factor de crecimiento epidérmico
CU24534B1 (es) 2017-11-06 2021-07-02 Ct Inmunologia Molecular Adyuvantes nano-particulados que contienen variantes sintéticas del gangliósido gm3

Also Published As

Publication number Publication date
KR102728174B1 (ko) 2024-11-11
EA202091116A1 (ru) 2020-09-24
US20240131152A1 (en) 2024-04-25
EP3711775A1 (en) 2020-09-23
TW201927804A (zh) 2019-07-16
CU24534B1 (es) 2021-07-02
US11806396B2 (en) 2023-11-07
AU2018359358B2 (en) 2022-08-04
JP7332592B2 (ja) 2023-08-23
CN111295200B (zh) 2025-05-16
AU2018359358A1 (en) 2020-06-11
WO2019086056A1 (es) 2019-05-09
JP2021501792A (ja) 2021-01-21
SG11202004180SA (en) 2020-06-29
US20200268878A1 (en) 2020-08-27
MY204283A (en) 2024-08-21
CO2020006548A2 (es) 2020-08-21
CA3079105A1 (en) 2019-05-09
CN111295200A (zh) 2020-06-16
TWI719351B (zh) 2021-02-21
BR112020008668A2 (pt) 2020-10-06
US12280109B2 (en) 2025-04-22
ZA202003218B (en) 2022-05-25
KR20200086315A (ko) 2020-07-16
CU20170137A7 (es) 2019-06-04
MX2020004644A (es) 2020-07-24
NZ764565A (en) 2024-02-23

Similar Documents

Publication Publication Date Title
AR114139A1 (es) Nano-partículas que contienen variantes sintéticas del gangliósido gm3 como adyuvantes en vacunas
MX363529B (es) Vesículas de membrana externa.
EP3556353A3 (en) Lipid nanoparticle vaccine adjuvants and antigen delivery systems
MX2019007910A (es) Conjugados de polipeptido-antigeno con aminoacidos no naturales.
MX2019004913A (es) Vacunas de nanoparticulas lipidicas que comprenden acido ribonucleico mensajero (arnm).
RU2017104529A (ru) Композиции neisseria meningitidis и способы их применения
CR20200408A (es) Nuevos péptidos y nuevas combinaciones de péptidos para el uso en la misma terapia contra el cáncer epitelial de ovario y otros tipos de cáncer (divisional 2018-0027).
NZ733168A (en) Novel immunotherapy against several tumors, such as lung cancer, including nsclc
EP4253401A3 (en) Personalized immunotherapy against several neuronal and brain tumors
CL2015001902A1 (es) Vacunas con mayor densidad de antigeno carbohidrato y nuevo adyuvante de saponina (divisional).
BR112016015422A2 (pt) formulações de vacina de frasco único
EA201790239A1 (ru) Молекула-носитель для антигенов
EA201892735A1 (ru) Состав вакцины против hiv
PH12015501716B1 (en) Anti-mycoplasma spp. subunit vaccine
MX2019006105A (es) Conjugados de vmen-antigeno y uso de los mismos.
MX349657B (es) Composiciones de vacuna de matriz de proteína que incluyen policationes.
EA201790558A1 (ru) Композиция с пониженной иммуногенностью
PH12014501795A1 (en) Rota virus subunit vaccines and methods of making and use thereof
MX2019006104A (es) Conjugados inmunogenicos y uso de los mismos.
PL404229A1 (pl) Wyizolowany immunogenny antygen bakteryjny i jego zastosowanie w profilaktyce i leczeniu zakażeń wywołanych przez Gram-ujemne bakterie
EA201692375A1 (ru) Антитело-опосредованные вакцины и способы их применения для получения быстрых зрелых иммунных ответов
BR112014026407A2 (pt) formulação de vacina líquida
EA201200538A1 (ru) Арабиногалактан для повышения приобретенного иммунного ответа
RU2015113230A (ru) Домен CNAB SDRE STAPHYLOCOCCUS AUREUS и его применение для вакцинации
BR112014001287A2 (pt) vacina recombinante do vírus da leucemia felina contendo gene otimizado do envelope do vírus da leucemia felina

Legal Events

Date Code Title Description
FC Refusal